- Discussion to focus on recent achievements underscoring VBI’s commitment to the prevention and treatment of hepatitis B
- Virtual fireside chat with analyst Steven Seedhouse, Ph.D., to take place at 11:00 AM ET on December 8, 2020
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that members of the VBI leadership team will discuss the recent news and strategic outlook for the company’s hepatitis B (HBV) portfolio with covering analyst, Steven Seedhouse, Ph.D., from Raymond James & Associates, Inc. during a fireside chat at 11:00 AM ET on Tuesday, December 8, 2020. The discussion will highlight the Company’s two HBV pipeline candidates: VBI’s 3-antigen prophylactic HBV vaccine candidate, licensed in Israel as Sci-B-Vac®, and VBI-2601, a novel recombinant, immunotherapeutic candidate for the treatment of chronic HBV infection.
The fireside chat can be accessed live via the Events/Presentations page in the Investors section of the Company’s website, or by clicking this link: https://raymondjames.zoom.us/webinar/register/WN_i-eY5EFpSAWiQwiAub42Rg.
A replay of the webcast will be archived on the company’s website following the live conference call.
About Hepatitis B
Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with no available functional cure, many patients go on to develop liver cancers. An estimated 780,000 people die each year from complications of chronic HBV such as liver decompensation and hepatocellular carcinoma.